Leal Therapeutics

Leal Therapeutics is a developer of novel therapeutic services in Massachusetts. The company provides treatments for major central nervous system indications with urgent and unmet needs, enabling patients to access precision medicines. Leal’s leading investigational programs include LTX-002, an ASO therapy for patients with hereditary or sporadic amyotrophic lateral sclerosis (ALS), and LTX-001, a small molecule drug targeting schizophrenia. The company plans to submit IND applications for LTX-002 and LTX-001 by the end of 2024 and initiate first-in-human clinical trials in early 2025.